BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

09.03.2020

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

08.12.2020

BridgeBio Pharma, Inc. Reports Second Quarter 2020 Financial Results and Business Update

08.11.2020

BridgeBio Pharma Expands Reach Into China and Other Major Asian Markets Through Strategic Collaboration With Perceptive Advisors-Founded Company, LianBio

08.11.2020

Ivy Brain Tumor Center and BridgeBio Pharma’s QED Therapeutics Announce Dosing of First Patient in Investigator-Initiated Phase 0/2 Clinical Trial of Infigratinib in Recurrent Glioblastoma

07.28.2020

BridgeBio Pharma’s QED Therapeutics Doses First Child in Phase 2 Clinical Trial of the Investigational Medicine Infigratinib in Achondroplasia

07.15.2020

BridgeBio Pharma’s Phoenix Tissue Repair to Highlight Interim Phase 1/2 Study Data in a Presentation at the Society for Pediatric Dermatology’s 45th Annual Meeting

07.10.2020

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

07.06.2020

BridgeBio Pharma, Inc. Appoints Biotech Trailblazers Brent Saunders and Randy Scott and Renowned Economist Andrew Lo to Board of Directors

06.24.2020

BridgeBio Pharma, Inc. and University of Florida Establish Collaboration to Advance Therapies for Genetically Driven Diseases

06.18.2020

BridgeBio Pharma, Inc. Enters Into Collaboration Agreement With Johns Hopkins University to Accelerate Development of New Medicines in Genetically Driven Diseases

06.18.2020

BridgeBio Pharma’s ML Bio Solutions Announces Dosing of First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)

06.11.2020

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06.05.2020

BridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma at the American Society of Clinical Oncology 2020 Virtual Scientific Program

05.29.2020

BridgeBio Pharma’s Phoenix Tissue Repair Provides Updates to its Recessive Dystrophic Epidermolysis Bullosa (RDEB) Program and Announces New Leadership Appointments

05.13.2020

BridgeBio Pharma, Inc. Reports First Quarter 2020 Financial Results and Business Update

05.13.2020

BridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in Achondroplasia

05.11.2020

BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference

05.06.2020

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05.05.2020

A Letter to Our Shareholders from CEO Neil Kumar

04.23.2020

news

Catch up on news from BridgeBio and its companies and follow developments about the promising treatments in our pipeline. Follow us on LinkedIn and Twitter to keep up with all the latest news.

Links to an external site